Jimandin

Active Ingredient:: Sitagliptin
Origin:: EU

Jimandin (Sitagliptin)

Q: What is Jimandin used for?

Jimandin contains sitagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus. It is used to improve blood glucose control when combined with diet, exercise, and other antidiabetic agents as prescribed by a healthcare professional.

Q: How does sitagliptin work in the body?

Sitagliptin blocks the enzyme dipeptidyl peptidase‑4, which normally breaks down the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin release and reduces glucagon secretion, leading to lower blood glucose levels.

Q: What is the usual dose of Jimandin?

The appropriate dose of Jimandin is determined by the prescribing clinician based on the patient’s renal function, glycaemic targets, and concomitant therapies. Dosage adjustments may be required for patients with impaired kidney function.

Q: Is Jimandin safe during pregnancy or breastfeeding?

Safety of sitagliptin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

Q: How do I order Jimandin from GNH India?

To request Jimandin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Jimandin compare with other antidiabetic classes?

Compared with sulfonylureas, sitagliptin has a lower risk of causing hypoglycaemia because its insulin‑stimulating effect is glucose‑dependent. Unlike metformin, it does not affect gastrointestinal absorption, and it can be combined with both agents for additive glucose‑lowering effects.

Q: What are the storage requirements for Jimandin?

Jimandin tablets should be stored at room temperature, below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Q: How is Jimandin administered?

Jimandin is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with water and not crushed or chewed, unless otherwise directed by a healthcare professional.

Q: What are the most serious risks associated with Jimandin?

Serious adverse events include pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin disorders like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or difficulty breathing.

Q: Who should not use Jimandin?

Jimandin is contraindicated in patients with a known hypersensitivity to sitagliptin or any component of the formulation. Caution is also advised for individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²) unless dose adjustments are made by a physician.

Sitagliptin, the active ingredient in Jimandin, is a DPP-4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving blood glucose control when used with diet and exercise.
GNH India supplies Jimandin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Medochemie Ltd.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Jimandin (sitagliptin) belongs to the DPP‑4 inhibitor class and is used to manage hyperglycaemia in type 2 diabetes.

Type 2 diabetes mellitus: improves glycaemic control by increasing insulin secretion and decreasing glucagon release.
Adjunct to diet and exercise: helps patients achieve target HbA1c levels when lifestyle measures alone are insufficient.
Combination with metformin: provides additional glucose‑lowering effect for patients inadequately controlled on metformin alone.

How It Works

Sitagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which degrades the incretin hormones GLP‑1 and GIP. By preventing this degradation, sitagliptin raises endogenous incretin levels, leading to glucose‑dependent stimulation of insulin release from pancreatic β‑cells and suppression of glucagon secretion from α‑cells, thereby lowering plasma glucose concentrations.

Side Effects

Sitagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects

Nausea: mild to moderate discomfort in the stomach.
Headache: transient pain or pressure in the head.
Upper respiratory tract infection: symptoms such as sore throat, cough, or nasal congestion.

Serious or Rare Side Effects

Pancreatitis: severe abdominal pain that may indicate inflammation of the pancreas.
Severe allergic reactions: rash, itching, swelling, or difficulty breathing.
Joint pain: unexplained arthralgia that can be disabling.
Bullous pemphigoid: rare skin blistering disorder.

Precautions & Warnings

Before initiating Jimandin, clinicians should consider several safety aspects.

Renal function: assess eGFR and adjust dose in moderate to severe impairment.
Pancreatitis history: avoid use in patients with prior pancreatitis.
Hypersensitivity: discontinue if signs of allergic reaction appear.
Elderly patients: monitor closely for dehydration and renal changes.
Concomitant medications: review for drugs that may affect glucose levels.
Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Sitagliptin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

Co‑administration with another DPP‑4 inhibitor (e.g., saxagliptin): duplicate pharmacologic effect.
Strong renal‑impairing agents in patients with eGFR <30 mL/min/1.73 m²: risk of accumulation.

Moderate Interactions (Monitor Closely)

Insulin or sulfonylureas: heightened risk of hypoglycaemia; dose adjustments may be needed.
Rifampin: may lower sitagliptin plasma concentrations, reducing effectiveness.
Diuretics: monitor electrolytes and renal function as volume changes can affect drug clearance.

Frequently Asked Questions

Jimandin contains sitagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus. It is used to improve blood glucose control when combined with diet, exercise, and other antidiabetic agents as prescribed by a healthcare professional.

Sitagliptin blocks the enzyme dipeptidyl peptidase‑4, which normally breaks down the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin release and reduces glucagon secretion, leading to lower blood glucose levels.

The appropriate dose of Jimandin is determined by the prescribing clinician based on the patient’s renal function, glycaemic targets, and concomitant therapies. Dosage adjustments may be required for patients with impaired kidney function.

Safety of sitagliptin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Jimandin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, sitagliptin has a lower risk of causing hypoglycaemia because its insulin‑stimulating effect is glucose‑dependent. Unlike metformin, it does not affect gastrointestinal absorption, and it can be combined with both agents for additive glucose‑lowering effects.

Jimandin tablets should be stored at room temperature, below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Jimandin is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with water and not crushed or chewed, unless otherwise directed by a healthcare professional.

Serious adverse events include pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin disorders like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or difficulty breathing.

Jimandin is contraindicated in patients with a known hypersensitivity to sitagliptin or any component of the formulation. Caution is also advised for individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²) unless dose adjustments are made by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 15 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.